1037649--4/2/2007--INTERLEUKIN_GENETICS

related topics

{product, liability, claim}

{product, candidate, development}

{acquisition, growth, future}

{property, intellectual, protect}

{product, market, service}

{tax, income, asset}

{control, financial, internal}

{stock, price, share}

{stock, price, operating}

{customer, product, revenue}

{personnel, key, retain}

{interest, director, officer}

{competitive, industry, competition}

The market for genetic risk assessment tests is unproven. Technological changes may cause our tests to become obsolete. We currently have only one customer for our genetic risk assessment tests upon whom we rely to perform sales, marketing and distribution functions on our behalf, which could limit our efforts to successfully market products. We have a history of operating losses and expect these losses to continue in the future. We are subject to government regulation, which may significantly increase our costs and delay introduction of future products. Because a single stockholder has a controlling percentage of our voting power, other stockholders voting power is limited. Our recent acquisition may not be profitable, and the integration of our businesses may be costly and difficult and may cause disruption to our business. An inability to manage our growth or successfully integrate acquired businesses could adversely affect our business. Intangible assets that we have recorded in connection with our acquisition of the Alan James Group could become impaired, requiring us to take significant charges against earnings. If we deliver products with defects, our credibility may be harmed, market acceptance of our products may decrease and we may be exposed to liability in excess of our product liability insurance coverage. The sales of branded nutritional supplements we recently acquired have been flat to slightly declining due to the segments we compete in (as the overall category consumption has declined year over year). This trend could continue and we may experience continued flatness or declines of those products. Our failure to appropriately respond to changing consumer preferences and demand for new products could significantly harm our customer relationships and product sales. Sales of our specific nutritional supplements and OTCeuticals could be negatively impacted by media attention or other news developments that challenge the safety and effectiveness of those specific nutritional products and OTCeuticals. The profitability of our consumer products businesses may suffer if we are unable to establish and maintain close working relationships with our customers. Period-to-period comparisons of our operating results may not be meaningful due to our recent acquisition. The market for personalized health is unproven. If we fail to obtain additional capital, or obtain it on unfavorable terms, then we may have to end our research and development programs and other operations. Our Series A Preferred Stock has certain rights that are senior to common stockholder rights and this may reduce the value of our common stock. If we are unsuccessful in establishing additional strategic alliances, our ability to develop and market products and services may be damaged. If we fail to obtain patent protection for our products and preserve our trade secrets, then competitors may develop competing products and services, which will likely decrease our sales and market share. Third parties may own or control patents or patent applications and require us to seek licenses, which could increase our costs or prevent us from developing or marketing our products or services. We could become subject to intense competition from other companies, which may damage our business. We may be subject to product liability claims that are costly to defend and that could limit our ability to use some technologies in the future. Ethical, legal and social issues related to genetic testing may reduce demand for our products. Our dependence on key executives and scientists could adversely impact the development and management of our business. In a circumstance in which Alticor enters a business in competition with our own, certain of our Directors might have a conflict of interest. We may be prohibited from fully using our net operating loss carryforwards, which could affect our financial performance. We do not expect to pay dividends for the foreseeable future and you should not expect to receive any funds without selling your shares of common stock, which you may only be able to do at a loss.

Full 10-K form ▸

1037649--4/2/2007--INTERLEUKIN_GENETICS_INC